Current application and bioavailability of drug-eluting stents

Bibliography

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245
   PubMed Web of Science ®Google Scholar
• Bashore TM, Balter S, Barac A, et al. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update: a report of the American College of Cardiology Foundation Task Force on Expert Consensus documents developed in collaboration with the Society of Thoracic Surgeons and Society for Vascular Medicine. J Am Coll Cardiol 2012;59:2221-305
   PubMed Web of Science ®Google Scholar
• Sousa JE CM, Abizaid A, Abizaid AS, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5
   PubMed Web of Science ®Google Scholar
• Bangalore S, Amoroso N, Fusaro M, et al. Outcomes with various drug-eluting or bare metal stents in patients with st-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. Circ Cardiovasc Intv 2013;6:378-90
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23
   PubMed Web of Science ®Google Scholar
• Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22:1769-76
   PubMed Web of Science ®Google Scholar
• Inoue T, Croce K, Morooka T, et al. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057-66
   PubMed Web of Science ®Google Scholar
• Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-63
   PubMed Web of Science ®Google Scholar
• Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart 2003;89:133-8
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-20
   PubMed Web of Science ®Google Scholar
• Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biological responses in stented arteries. Cardiovasc Res 2013;99:353-63
   PubMed Web of Science ®Google Scholar
• Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8
   PubMed Web of Science ®Google Scholar
• Steffel J, Eberli FR, Luscher TF, Tanner FC. Drug-eluting stents - what should be improved? Ann Med 2008;40:242-52
   PubMed Web of Science ®Google Scholar
• Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81
   PubMed Web of Science ®Google Scholar
• Rodgers CD. Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. Rev Cardiovasc Med 2002;3(Suppl 5):S10-15
   PubMedGoogle Scholar
• Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: part I. Circulation 2003;107:2274-9
   PubMed Web of Science ®Google Scholar
• Abizaid A, Costa JR Jr. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv 2010;3:384-93
   PubMed Web of Science ®Google Scholar
• Flechner SM, Gurkan A, Hartmann A, et al. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation 2013;95:1233-41
   PubMed Web of Science ®Google Scholar
• Weisz G, Leon MB, Holmes DR Jr, et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009;53:1488-97
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48
   PubMed Web of Science ®Google Scholar
• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7
   PubMed Web of Science ®Google Scholar
• Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994;5:1041-50
   PubMedGoogle Scholar
• Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2009;2:1248-59
   PubMed Web of Science ®Google Scholar
• Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7
   PubMed Web of Science ®Google Scholar
• Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010;375:1090-9
   PubMed Web of Science ®Google Scholar
• Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46
   PubMed Web of Science ®Google Scholar
• Tada T, Byrne RA, Cassese S, et al. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. Am Heart J 2013;165:80-6
   PubMed Web of Science ®Google Scholar
• Qiao S, Chen L, Chen S, et al. One-year outcomes from an all-comers chinese population of patients implanted with the resolute zotarolimus-eluting stent. Am J Cardiol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Belardi JA, Widimsky P, Neumann FJ, et al. Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study. J Interv Cardiol 2013;26:515-23
   PubMed Web of Science ®Google Scholar
• Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013;6:914-22
   PubMed Web of Science ®Google Scholar
• Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9
   PubMed Web of Science ®Google Scholar
• Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol 2009;54:269-76
   PubMed Web of Science ®Google Scholar
• Park KW, Lim WH, Ahn HS, et al. Everolimus- versus sirolimus-eluting stents for the treatment of unprotected left main coronary artery stenosis (results from the EXCELLENT registry). Int J Cardiol 2013;167:2738-44
   Google Scholar
• Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011;57:1700-8
   PubMed Web of Science ®Google Scholar
• Kounis NG, Kounis GN, Soufras GD. Kounis syndrome: a potential cause of simultaneous multivessel coronary spasm and thrombosis after drug-eluting stent implantation. J Invasive Cardiol 2007;19:200-1
   PubMedGoogle Scholar
• Meredith IT, Verheye S, Weissman NJ, et al. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention 2013;9:308-15
   PubMed Web of Science ®Google Scholar
• Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73
   PubMed Web of Science ®Google Scholar
• Raungaard B. A prospective, Randomized, "All comers" trial of biodegradable polymer-coated Biolimus-eluting stents vs Biocompatible polymer-coated Zotarolimus-eluting stnets: SORT-OUT VI trial. TCT, San Francisco, CA; 2013
   Google Scholar
• Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013;381:661-9
   PubMed Web of Science ®Google Scholar
• Byrne RA, Kastrati A, Massberg S, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011;58:1325-31
   PubMed Web of Science ®Google Scholar
• Han YL, Zhang L, Yang LX, et al. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. EuroIntervention 2012;8:815-22
   PubMedGoogle Scholar
• Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-22
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kubica J, Castriota F, et al. Safety and efficacy of biodegradable vs durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 2011;7:985-94
   PubMedGoogle Scholar
• Hamon M, Niculescu R, Deleanu D, et al. Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study. EuroIntervention 2013;8:1006-11
   PubMed Web of Science ®Google Scholar
• Grube E. Biofreedom first-in-man 2 year outcomes. TCT, San Francisco, CA (abstract); 2001
   Google Scholar
• Urban P, Abizaid A, Chevalier B, et al. Rationale and design of the LEADERS FREE trial: a randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J 2013;165:704-9
   PubMed Web of Science ®Google Scholar
• Costa JR Jr, Abizaid A, Costa R, et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc Interv 2009;2:422-7
   PubMed Web of Science ®Google Scholar
• Costa JR Jr, Oliveira BA, Abizaid A, et al. Clinical, angiographic and intravascular ultrasound results of the VestSaync II trial. Catheter Cardiovasc Interv 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-9
   PubMed Web of Science ®Google Scholar
• King L, Byrne RA, Mehilli J, et al. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheter Cardiovasc Interv 2013;81:23-8
   PubMed Web of Science ®Google Scholar
• Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-9
   PubMed Web of Science ®Google Scholar
• Patel N, Banning AP. Bioabsorbable scaffolds for the treatment of obstructive coronary artery disease: the next revolution in coronary intervention? Heart 2013;99:1236-43
   PubMed Web of Science ®Google Scholar
• Nishio S, Kosuga K, Igaki K, et al. Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: igaki-Tamai stents. Circulation 2012;125:2343-53
   PubMed Web of Science ®Google Scholar
• Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-75
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910
   PubMed Web of Science ®Google Scholar
• Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2012;7:1060-1
   PubMed Web of Science ®Google Scholar
• Bartorelli A. ABSROB EXTEND: Interim Report on the 6-month clinical outcome from the first 250 patients registered. TCT, Miami; 2012
   Google Scholar
• Souza RA. Side Branch patency after implantation of the novel DESolve bioresorbable vascular scaffold system in the treatment of de novo coronary lesions. TCT, San Francisco; 2013
   Google Scholar
• Abizaid A. 12-month angiographic and clinical results of the ReZolve sirolimus-eluting bioresorbable coronary scaffold: the RESTORE trial. TCT, San Francisco; 2013
   Google Scholar
• Bauer T, Nienaber CA, Akin I, et al. Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry. Clin Res Cardiol 2011;100:701-9
   PubMed Web of Science ®Google Scholar
• Guo N, Maehara A, Mintz GS, et al. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation 2010;122:1077-84
   PubMed Web of Science ®Google Scholar
• Boden H, van der Hoeven BL, Liem SS, et al. Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention 2012;7:1021-9
   PubMedGoogle Scholar
• Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007;20:282-91
   PubMed Web of Science ®Google Scholar
• Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv 2009;2:515-23
   PubMed Web of Science ®Google Scholar
• Diaz de la Llera LS, Ballesteros S, Nevado J, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007;154:164.e1-6
   Google Scholar
• Gao H, Yan HB, Zhu XL, et al. Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl) 2007;120:863-7
   PubMed Web of Science ®Google Scholar
• Juwana YB, Suryapranata H, Ottervanger JP, et al. Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 2009;104:205-9
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee JH, Lee SW, et al. Long-term safety and efficacy of sirolimus- vs paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol 2011;147:253-7
   PubMed Web of Science ®Google Scholar
• Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007;49:1924-30
   PubMed Web of Science ®Google Scholar
• Sanchez PL, Gimeno F, Ancillo P, et al. Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circ Cardiovasc Interv 2010;3:297-307
   PubMed Web of Science ®Google Scholar
• Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv 2011;4:14-23
   PubMed Web of Science ®Google Scholar
• Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007;50:138-45
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Gambetti S, et al. Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). Int J Cardiol 2013;165:134-41
   PubMed Web of Science ®Google Scholar
• Vink MA, Dirksen MT, Suttorp MJ, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 2011;4:24-9
   PubMed Web of Science ®Google Scholar
• De Luca G, Dirksen MT, Spaulding C, et al. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol 2013;111:1295-304
   PubMed Web of Science ®Google Scholar
• Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90
   PubMed Web of Science ®Google Scholar
• Thim T, Maeng M, Kaltoft A, et al. Zotarolimus-eluting vs sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. Eur J Clin Invest 2012;42:1047-54
   PubMed Web of Science ®Google Scholar
• Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol 2012;60:381-7
   PubMed Web of Science ®Google Scholar
• Waksman R, Barbash IM, Dvir D, et al. Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. Am J Cardiol 2012;109:1288-94
   PubMed Web of Science ®Google Scholar
• Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1396-405
   PubMed Web of Science ®Google Scholar
• Kang WC, Ahn T, Lee K, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 2011;7:936-43
   PubMedGoogle Scholar
• Kedhi E, Gomes M, Joesoef KS, et al. Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial. EuroIntervention 2012;7:1376-85
   PubMedGoogle Scholar
• Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87
   PubMed Web of Science ®Google Scholar
• Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72
   PubMed Web of Science ®Google Scholar
• Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629-38
   PubMed Web of Science ®Google Scholar
• The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-25
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367:2375-84
   PubMed Web of Science ®Google Scholar
• De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991-1001
   PubMed Web of Science ®Google Scholar
• Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010;121:2645-53
   PubMed Web of Science ®Google Scholar
• Lee JY, Park DW, Yun SC, et al. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry. J Am Coll Cardiol 2009;54:853-9
   PubMed Web of Science ®Google Scholar
• Naganuma T, Latib A, Basavarajaiah S, et al. The long-term clinical outcome of T-stenting and small protrusion technique for coronary bifurcation lesions. JACC Cardiovasc interv 2013;6:554-61
   PubMed Web of Science ®Google Scholar
• Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J Am Coll Cardiol 2011;57:538-45
   PubMed Web of Science ®Google Scholar
• Briguori C, Condorelli G, Airoldi F, et al. Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol 2007;99:779-84
   PubMed Web of Science ®Google Scholar
• Javaid A, Steinberg DH, Buch AN, et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation 2007;116(11 Suppl):I200-6
   Google Scholar
• Kim YH, Park DW, Ahn JM, et al. Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study. JACC Cardiovasc Interv 2012;5:708-17
   PubMed Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009;53:1760-8
   PubMed Web of Science ®Google Scholar
• Minha S, Barbash IM, Dvir D, et al. Second-generation everolimus-eluting stents compared to first-generation drug-eluting stents in patients treated for multivessel disease. J Interv Cardiol 2013;26:561-9
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011;364:1718-27
   PubMed Web of Science ®Google Scholar
• Qiao Y, Ma C, Nie S, et al. Twelve months clinical outcome of drug-eluting stents implantation or coronary artery bypass surgery for the treatment of diabetic patients with multivessel disease. Clin Cardiol 2009;32:E24-30
   Google Scholar
• Tarantini G, Ramondo A, Napodano M, et al. PCI versus CABG for multivessel coronary disease in diabetics. Catheter Cardiovasc Interv 2009;73:50-8
   PubMed Web of Science ®Google Scholar
• Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26
   PubMed Web of Science ®Google Scholar
• Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet 2011;378:1071-8
   PubMed Web of Science ®Google Scholar
• Brodie BR, Wilson H, Stuckey T, et al. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc Interv 2009;2:1105-12
   PubMed Web of Science ®Google Scholar
• Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. JACC Cardiovasc Interv 2010;3:1262-73
   PubMed Web of Science ®Google Scholar
• Kitabata H, Loh JP, Pendyala LK, et al. Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits. Am J Cardiol 2013;112:61-7
   PubMed Web of Science ®Google Scholar
• Costopoulos C, Latib A, Naganuma T, et al. Comparison of first- and second-generation drug-eluting stents in saphenous vein grafts used as aorto-coronary conduits. Am J Cardiol 2013;112:318-22
   PubMed Web of Science ®Google Scholar
• Brilakis ES, Lichtenwalter C, Abdel-karim AR, et al. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 2011;4:176-82
   PubMed Web of Science ®Google Scholar
• Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-7
   PubMed Web of Science ®Google Scholar
• Goswami NJ, Gaffigan M, Berrio G, et al. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie “Real World” Stent Registry. Catheter Cardiovasc Interv 2010;75:93-100
   PubMed Web of Science ®Google Scholar
• Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007;20:458-65
   PubMedGoogle Scholar
• Okabe T, Lindsay J, Torguson R, et al. Can direct stenting in selected saphenous vein graft lesions be considered an alternative to percutaneous intervention with a distal protection device? Catheter Cardiovasc Interv 2008;72:799-803
   PubMed Web of Science ®Google Scholar
• Ramana RK, Ronan A, Cohoon K, et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv 2008;71:886-93
   PubMed Web of Science ®Google Scholar
• van Twisk PH, Daemen J, Kukreja N, et al. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. EuroIntervention 2008;4:311-17
   PubMedGoogle Scholar
• Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007;50:261-7
   PubMed Web of Science ®Google Scholar
• Okabe T, Lindsay J, Buch AN, et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 2008;102:530-4
   PubMed Web of Science ®Google Scholar
• De Felice F, Fiorilli R, Parma A, et al. Five-year outcomes in patients with chronic total coronary occlusion treated with drug-eluting vs bare-metal stents: a case-control study. Can J Cardiol 2013;29:945-50
   PubMed Web of Science ®Google Scholar
• Mehran R, Claessen BE, Godino C, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv 2011;4:952-61
   PubMed Web of Science ®Google Scholar
• Patel MR, Marso SP, Dai D, et al. Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005-2008. JACC Cardiovasc Interv 2012;5:1054-61
   PubMed Web of Science ®Google Scholar
• Thuesen L, Kelbaek H, Klovgaard L, et al. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). Am Heart J 2006;152:1140-5
   PubMed Web of Science ®Google Scholar
• Kumsars I. Randomized comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch. TCT; San Francisco, CA: 2013
   Google Scholar
• Grube E, Buellesfeld L, Neumann FJ, et al. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol 2007;99:1691-7
   PubMed Web of Science ®Google Scholar
• Buysschaert I, Dubois CL, Dens J, et al. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention 2013;9:573-81
   PubMedGoogle Scholar
• Leon MB. The Tryton Bifurcation Trial: A randomized comparison of a provisional one-stent vs a dedicated two-stent strategy for true bifurcation coronary lesions. TCT, San Francisco, CA; 2013
   Google Scholar